Fact-check

Quoted analysis claiming high-growth founders face something close to a doubling of the top effective CGT rate

This quoted analysis is directionally consistent with the no-relief founder cases already in the corpus, but it still depends on important hidden assumptions. The Budget does replace the 50 per cent CGT discount with inflation indexation plus a 30 per cent minimum tax from 1 July 2027, which can move a founder from something like a 23.5 per cent effective rate on discounted gains to a rate much closer to the top marginal rate in a high-real-gain scenario. But the stronger 'close to a doubling' framing still assumes individual ownership, little or no concession relief, mostly post-2027 gains, and a business exit where the gain remains largely real rather than inflation-indexed away.

2 requires assumptions

Prefills a fully post-2027 founder exit at the top marginal rate so the quoted 'near doubling' founder-tax claim can be pressure-tested against explicit concession assumptions.

Submitted text

"CGT: for high-growth founders, the reform is close to a doubling of the top effective rate. For a founder whose shares compound at high rates, almost all of the exit value is real gain, so the effective tax rate tends toward the top marginal rate, around 45–47% depending on Medicare levy and exact tax settings."

Per-claim verification

requires assumptions 86% confidence

For some high-growth founder exits, the reform can take the effective tax burden from roughly the old discounted-gain rate to something close to double that level.

“for high-growth founders, the reform is close to a doubling of the top effective rate”

This is directionally plausible in the narrow no-relief founder scenario already modelled on the site. Under the old system, a founder on the top marginal rate could face an effective rate of roughly 23.5 per cent on a discounted capital gain, while the post-2027 system can push the effective rate much closer to the top marginal rate where indexation provides little shelter relative to the real gain. But 'close to a doubling' is not a universal founder result: it depends on the gain being mostly post-2027, on relief not materially reducing the gain, and on the founder being taxed personally at or near the top rate.

Assumptions required

  • Assumes the founder is an individual taxed at or near the top marginal rate.
  • Assumes small business CGT concessions do not materially reduce or disregard the gain.
  • Assumes most of the economically relevant gain is exposed to the post-1 July 2027 regime.

Alternative defensible framings

  • In a no-relief top-rate founder scenario, the reform can move the effective tax burden from the old discounted-gain rate to something much closer to the full marginal rate.
  • Whether that is 'close to double' depends on the founder's rate, holding period, inflation path, and concession eligibility.
requires assumptions 88% confidence

In a high-real-gain founder exit with little shelter from indexation or concessions, the effective tax rate can approach the top marginal personal rate, around 45 to 47 per cent depending on Medicare and settings.

“For a founder whose shares compound at high rates, almost all of the exit value is real gain, so the effective tax rate tends toward the top marginal rate, around 45–47% depending on Medicare levy and exact tax settings.”

This is basically the zero-cost-base founder logic expressed in broader high-growth terms. If the founder's gain is overwhelmingly real rather than inflationary, indexation does relatively little work and the post-2027 tax treatment can converge toward the top marginal personal rate in a no-relief case. But the statement still needs narrowing: the actual effective rate varies with ownership structure, cost base, inflation, timing of accrual, and whether Subdivision 152 or other features materially reduce the gain.

Assumptions required

  • Assumes little shelter from cost-base uplift relative to the real gain.
  • Assumes the founder is taxed personally at or near the top marginal rate including Medicare.
  • Assumes no small business CGT concession materially reduces or disregards the gain.

Alternative defensible framings

  • Some high-real-gain founder exits can face a post-2027 effective rate much closer to the top marginal personal rate than under the old discount system.
  • The 45 to 47 per cent headline is a narrow no-relief benchmark, not a universal founder outcome.